# A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Source: https://onco.cc/trials/nct06134375/  
OnCo record `nct06134375` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of capecitabine and pembrolizumab in triple-negative breast cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.

## Summary

A Study of Tetrathiomolybdate (TM) Plus Capecitabine is a phase 1/2, randomised interventional study registered as NCT06134375 by Dartmouth-Hitchcock Medical Center, with a registry enrolment figure of 204 participants, started 2024-11-26 and due to reach its primary completion in 2031-06-26. Interventions recorded: Tetrathiomolybdate; Capecitabine; Pembrolizumab. Conditions listed: Triple Negative Breast Cancer; Residual Disease. Triple-negative eligibility wording from the registry: "Patients must have histologically confirmed breast malignancy that is Triple negative tumors as defined as ER and PR \<1% and HER2 negative as per ASCO/CAP guidelines". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06134375
- Phase: 1/2
- Setting: Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients With Breast Cancer at High Risk of Recurrence
- Sponsor: Dartmouth-Hitchcock Medical Center
- Enrolled: 204

## Sources

- ClinicalTrials.gov NCT06134375: https://clinicaltrials.gov/study/NCT06134375

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06134375.json